Summary of Key Information:

Nature of Filing / Announcement: Outcome of Board Meeting

Corporate Actions:

Subsidiary Incorporation:

  • Approved incorporation of a new subsidiary company in India
  • Estimated aggregate capital outlay: ₹4,10,000/- (Rupees Four Lakh and Ten Thousand only)
  • Investment structure: Subscription to 41,000 equity shares of face value ₹10/- each
  • Company's shareholding: 82% of the subsidiary's paid-up equity share capital
  • Consideration method: Cash consideration
  • Industry: Pharmaceutical Industry
  • Country of Incorporation: India
  • Regulatory approvals required: Registrar of Companies approval and other applicable regulatory/statutory approvals

Auditor Appointments:

Internal Auditor:
  • Appointed: M/s. Ernst & Young LLP, Chartered Accountants
  • Term: 1 year for Financial Year 2026-2027
  • Profile: Professional services firm with over 30 years experience in Internal Audit, Risk and Consulting, Internal Controls, with global network of 45,000+ professionals across 180 countries
Cost Auditor:
  • Appointed: M/s. ABK & Associates, Cost Accountants, Mumbai
  • Term: 1 year for Financial Year 2026-2027
  • Profile: Firm established in 1989 with head office in Mumbai and branch offices in Indore, Delhi, and Vadodara, providing services including Cost Audit, Internal Audit, Management Consultancy, GST Advisory, and Strategic Business Advisory

Other Significant Information:

  • The subsidiary is proposed to be incorporated (background details not applicable)
  • All investments will be duly disclosed to stock exchanges as per applicable requirements